soul trial oral semaglutide cardiovascular outcomes trial Forecasting Milestones: A Predictive Analysis for Early Termination of the Study | Diabetes Therapy Cardiovascular Outcomes, Safety, and Tolerability

Our weight-loss injections are designed to support individuals seeking medical assistance in their weight-loss efforts

The back of the upper arm is FDA-approved for Ozempic injections

Our designated professionals can bring treatments to you and administer them in the comfort of your own home

Active Ingredient Semaglutide (GLP-1 Receptor Agonist) Pen Strength 0.5 mg Semaglutide per delivery solution Delivery Tool 1 Multi-dose Disposable Pen + 4 Needles + 4 Swabs Primary Manufacturer Alkem Laboratories Ltd Administration Route Subcutaneous Injection (Weekly baseline) Primary Indication Titration Phase / Step-up Cycle for Chronic Weight Loss & Diabetes Care